De Neve J, Elhabazi K, Gonzalez S, Herby C, Schneider S, Utard V, Fellmann-Clauss R, Petit-Demouliere N, Lecat S, Kremer M, Ces A, Daubeuf F, Martin C, Ballet S, Bihel F, Simonin F

J Med Chem. 2024 04 30;:

Characterization of anti-GASP motif antibodies that inhibit the interaction between GPRASP1 and G protein-coupled receptors.

Zeder-Lutz G, Bornert O, Fellmann-Clauss R, Knittel-Obrecht A, Tranchant T, Bouteben S, Kaeffer J, Quillet R, Villa P, Wagner R, Lecat S, Simonin F

Anal Biochem. 2023 01 30;:115062

Behavioral characterization, potential clinical relevance and mechanisms of latent pain sensitization.

Gerum M, Simonin F

Pharmacol Ther. 2021 Nov 8;:108032

Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

De Neve J, Barlow TMA, Tourwé D, Bihel F, Simonin F, Ballet S

RSC Med Chem. 2021 Jun 23;12(6):828-870

Identification of an -acylated-Arg-Leu-NH Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced Hyperalgesia.

Quillet R, Schneider S, Utard V, Drieu la Rochelle A, Elhabazi K, Henningsen JB, Gizzi P, Schmitt M, Kugler V, Simonneaux V, Ilien B, Simonin F, Bihel F

J Med Chem. 2021 May 19;:

GPRASP/ARMCX protein family: potential involvement in health and diseases revealed by their novel interacting partners.

Kaeffer J, Zeder-Lutz G, Simonin F, Lecat S

Curr Top Med Chem. 2020 Dec 1;:

Aminoguanidine hydrazone derivatives as non-peptide NPFF1 receptor antagonists reverse opioid induced hyperalgesia.

Hammoud H, Elhabazi K, Quillet R, Bertin I, Utard V, Laboureyras E, Bourguignon JJ, Bihel F, Simonnet G, Simonin F, Schmitt M

ACS Chem Neurosci. 2018 May 4;:

A bifunctional biased mu opioid agonist - neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.

Drieu la Rochelle A, Guillemyn K, Dumitrascuta M, Martin C, Utard V, Quillet R, Schneider S, Daubeuf F, Willemse T, Mampuys P, Maes BUW, Frossard N, Bihel F, Spetea M, Simonin F, Ballet S

Pain. 2018 Apr 26;:

Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide.

Roeckel LA, Utard V, Reiss D, Mouheiche J, Maurin H, Robé A, Audouard E, Wood JN, Goumon Y, Simonin F, Gaveriaux-Ruff C

Sci Rep. 2017 Sep;7(1):10406

Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages.

Waqas SFH, Hoang AC, Lin YT, Ampem G, Azegrouz H, Balogh L, Thuróczy J, Chen JC, Gerling IC, Nam S, Lim JS, Martinez-Ibañez J, Real JT, Paschke S, Quillet R, Ayachi S, Simonin F, Schneider EM, Brinkman JA, Lamming DW, Seroogy CM, Röszer T

J. Clin. Invest.. 2017 Jun;:

RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.

Elhabazi K, Humbert JP, Bertin I, Quillet R, Utard V, Schneider S, Schmitt M, Bourguignon JJ, Laboureyras E, Ben Boujema M, Simonnet G, Ancel C, Simonneaux V, Beltramo M, Bucher B, Sorg T, Meziane H, Schneider E, Petit-Demoulière B, Ilien B, Bihel F, Simonin F

Neuropharmacology. 2017 Mar;118:188-198

Opioid-induced hyperalgesia: Cellular and molecular mechanisms.

Roeckel LA, Le Coz GM, Gavériaux-Ruff C, Simonin F

Neuroscience. 2016 Dec;338:160-182

Development of Dipeptidic hGPR54 Agonists.

Doebelin C, Bertin I, Schneider S, Schmitt M, Bourguignon JJ, Ancel C, Simonneaux V, Simonin F, Bihel F

ChemMedChem. 2016 Oct;11(19):2147-2154

The effect of neuropeptide FF in the amygdala kindling model.

Buffel I, Meurs A, Portelli J, Raedt R, De Herdt V, Poppe L, De Meulenaere V, Wadman W, Bihel F, Schmitt M, Vonck K, Bourguignon JJ, Simonin F, Smolders I, Boon P

Acta Neurol. Scand.. 2016 Sep;134(3):181-8

Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.

Guillemyn K, Starnowska J, Lagard C, Dyniewicz J, Rojewska E, Mika J, Chung NN, Utard V, Kosson P, Lipkowski AW, Chevillard L, Arranz-Gibert P, Teixidó M, Megarbane B, Tourwé D, Simonin F, Przewlocka B, Schiller PW, Ballet S

J. Med. Chem.. 2016 Apr;59(8):3777-92

RF-amide neuropeptides and their receptors in Mammals: Pharmacological properties, drug development and main physiological functions.

Quillet R, Ayachi S, Bihel F, Elhabazi K, Ilien B, Simonin F

Pharmacol. Ther.. 2016 Apr;160:84-132

Effects of systematic N-terminus deletions and benzoylations of endogenous RF-amide peptides on NPFF1R, NPFF2R, GPR10, GPR54 and GPR103.

Rouméas L, Humbert JP, Schneider S, Doebelin C, Bertin I, Schmitt M, Bourguignon JJ, Simonin F, Bihel F

Peptides. 2015 Sep;71:156-61

Neuropeptide FF receptors as novel targets for limbic seizure attenuation.

Portelli J, Meurs A, Bihel F, Hammoud H, Schmitt M, De Kock J, Utard V, Humbert JP, Bertin I, Buffel I, Coppens J, Tourwe D, Maes V, De Prins A, Vanhaecke T, Massie A, Balasubramaniam A, Boon P, Bourguignon JJ, Simonin F, Smolders I

Neuropharmacology. 2015 Aug;95:415-23

Rapid and scalable synthesis of innovative unnatural α,β or γ-amino acids functionalized with tertiary amines on their side-chains.

Schneider S, Ftouni H, Niu S, Schmitt M, Simonin F, Bihel F

Org. Biomol. Chem.. 2015 Jul;13(25):7020-6

Development of a peptidomimetic antagonist of neuropeptide FF receptors for the prevention of opioid-induced hyperalgesia.

Bihel F, Humbert JP, Schneider S, Bertin I, Wagner P, Schmitt M, Laboureyras E, Petit-Demoulière B, Schneider E, Mollereau C, Simonnet G, Simonin F, Bourguignon JJ

ACS Chem Neurosci. 2015 Mar;6(3):438-45

Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses.

Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL

Nat. Genet.. 2000 Jun;25(2):195-200

Fiche personne Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques